Current Report Filing (8-k)
August 10 2017 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.
Date of Report: August 10, 2017
(Date of earliest event reported)
SciClone
Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
(State or other jurisdiction
of incorporation)
|
|
0-19825
(Commission File Number)
|
|
94-3116852
(IRS Employer
Identification Number)
|
|
|
|
950 Tower Lane, Suite 900,
Foster City, CA
(Address
of principal executive offices)
|
|
|
|
94404
(Zip Code)
|
(650)
358-3456
(Registrants telephone number, including area code)
Not Applicable
(Former
Name or Former Address, if changed since last report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☒
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this
chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On August 10, 2017, SciClone Pharmaceuticals, Inc. (the
Company
) issued a press release concerning the end of the go shop process under the terms of the Agreement and Plan of Merger, dated June 7, 2017, between the Company and a consortium consisting of entities
affiliated with GL Capital Management GP Limited (GL Capital), Bank of China Group Investment Limited (BOCGI), CDH Investments, Ascendent Capital Partners and Boying (collectively, the Buyer Consortium). A copy of
the press release issued by the Company is attached as Exhibit 99.1 hereto and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits
|
|
|
|
Exhibit No.
|
|
Description of Exhibit
|
|
|
99.1
|
|
Press Release dated August 10, 2017.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Dated: August 10, 2017
|
|
|
|
SCICLONE PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Wilson W. Cheung
|
|
|
|
|
|
|
Wilson W. Cheung
|
|
|
|
|
|
|
Chief Financial Officer and
Senior Vice
President, Finance
|
Exhibit Index
|
|
|
Exhibit No.
|
|
Description of Exhibit
|
|
|
99.1
|
|
Press Release dated August 10, 2017.
|
Sciclone (NASDAQ:SCLN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sciclone (NASDAQ:SCLN)
Historical Stock Chart
From Sep 2023 to Sep 2024